AP2011005611A0 - Amide compounds useful in therapy. - Google Patents

Amide compounds useful in therapy.

Info

Publication number
AP2011005611A0
AP2011005611A0 AP2011005611A AP2011005611A AP2011005611A0 AP 2011005611 A0 AP2011005611 A0 AP 2011005611A0 AP 2011005611 A AP2011005611 A AP 2011005611A AP 2011005611 A AP2011005611 A AP 2011005611A AP 2011005611 A0 AP2011005611 A0 AP 2011005611A0
Authority
AP
ARIPO
Prior art keywords
therapy
compounds useful
amide compounds
amide
useful
Prior art date
Application number
AP2011005611A
Other languages
English (en)
Inventor
Florian Wakenhut
Toby James Underwood
Karl Richard Gibson
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of AP2011005611A0 publication Critical patent/AP2011005611A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
AP2011005611A 2008-09-18 2009-09-16 Amide compounds useful in therapy. AP2011005611A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9790208P 2008-09-18 2008-09-18
PCT/IB2009/054038 WO2010032200A1 (en) 2008-09-18 2009-09-16 Amide compounds useful in therapy

Publications (1)

Publication Number Publication Date
AP2011005611A0 true AP2011005611A0 (en) 2011-04-30

Family

ID=41269630

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005611A AP2011005611A0 (en) 2008-09-18 2009-09-16 Amide compounds useful in therapy.

Country Status (20)

Country Link
US (2) US8232269B2 (enExample)
EP (1) EP2350017A1 (enExample)
JP (1) JP2012502975A (enExample)
KR (1) KR20110044304A (enExample)
CN (1) CN102159548A (enExample)
AP (1) AP2011005611A0 (enExample)
AU (1) AU2009294290B2 (enExample)
BR (1) BRPI0918935A2 (enExample)
CA (1) CA2735931A1 (enExample)
CL (1) CL2011000570A1 (enExample)
CO (1) CO6351734A2 (enExample)
DO (1) DOP2011000083A (enExample)
EA (1) EA201100368A1 (enExample)
EC (1) ECSP11010901A (enExample)
IL (1) IL211479A0 (enExample)
MA (1) MA32642B1 (enExample)
MX (1) MX2011002899A (enExample)
PE (1) PE20110793A1 (enExample)
WO (1) WO2010032200A1 (enExample)
ZA (1) ZA201102690B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5964407B2 (ja) * 2011-04-21 2016-08-03 オリオン コーポレーション アンドロゲン受容体調節カルボキシアミド
EP2734042B1 (en) * 2011-07-21 2017-02-01 The Regents Of The University Of California Targeting gli proteins in human cancer by small molecules
US9416109B2 (en) 2012-02-17 2016-08-16 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
EP2700635A1 (en) 2012-08-20 2014-02-26 Basf Se 5-Trifluoromethylpyrazole amides having herbicidal activity
WO2014116651A1 (en) 2013-01-23 2014-07-31 The Regents Of The University Of California Targeting gli proteins in human cancer by small molecules
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2014143617A1 (en) * 2013-03-14 2014-09-18 Teva Women's Health, Inc. Deuterium-enriched tanaproget and processes for its preparation
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US20190321363A1 (en) * 2016-06-20 2019-10-24 Dr. Reddy's Laboratories Limited Process for the preparation of elagolix sodium and its polymorph
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3,3-二氟环丁烷甲酸的方法
EP3946606B1 (en) 2019-03-27 2025-01-01 Insilico Medicine IP Limited Bicyclic jak inhibitors and uses thereof
EP4053124A1 (en) * 2019-10-28 2022-09-07 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
WO2023217203A2 (zh) * 2022-05-12 2023-11-16 西北农林科技大学 二苯基吡唑类化合物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604218A1 (en) * 2005-04-20 2006-10-26 Pfizer Limited Pyrazole derivatives as progesterone receptor antagonists
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
EA201100368A1 (ru) 2011-12-30
US20100249091A1 (en) 2010-09-30
CL2011000570A1 (es) 2011-06-17
PE20110793A1 (es) 2011-10-31
ZA201102690B (en) 2011-12-28
AU2009294290A1 (en) 2010-03-25
US20120316150A1 (en) 2012-12-13
EP2350017A1 (en) 2011-08-03
MA32642B1 (fr) 2011-09-01
CO6351734A2 (es) 2011-12-20
KR20110044304A (ko) 2011-04-28
AU2009294290B2 (en) 2012-08-30
IL211479A0 (en) 2011-05-31
CN102159548A (zh) 2011-08-17
US8232269B2 (en) 2012-07-31
DOP2011000083A (es) 2011-03-31
BRPI0918935A2 (pt) 2015-12-01
MX2011002899A (es) 2011-04-11
JP2012502975A (ja) 2012-02-02
ECSP11010901A (es) 2011-04-29
WO2010032200A1 (en) 2010-03-25
CA2735931A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
IL206654A0 (en) Combination therapy
IL213619A0 (en) Treatment
GB0802116D0 (en) Treatment
ZA201102690B (en) Amide compounds useful in therapy
GB0822011D0 (en) Treatment
GB0719518D0 (en) Therapy
GB0811992D0 (en) Treatment
GB0812012D0 (en) Use
GB0803948D0 (en) Combination therapy
GB0820972D0 (en) Treatment
GB0905087D0 (en) Cypardon 2
EP2265112A4 (en) TREATMENT UNIT FOR SOFTWOOD
GB0805912D0 (en) Treatment
GB0807621D0 (en) Use
GB0700635D0 (en) Therapy
GB0716072D0 (en) Therapy
GB0812659D0 (en) Therapy
GB0813292D0 (en) Therapy
GB0821274D0 (en) Compounds for use in therapy
GB0810952D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances
GB0818712D0 (en) Therapeutic substances
GB0808042D0 (en) Advance 002
GB0703963D0 (en) Therapy